PPT-Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy
Author : tatiana-dople | Published Date : 2018-09-22
Yang Xin Paper presentation PNAS 2009 1061246294634 Introduction Antimicrobial drug development is increasingly lagging behind the evolution of antibiotic resistance
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Engineered bacteriophage targeting gene ..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy: Transcript
Yang Xin Paper presentation PNAS 2009 1061246294634 Introduction Antimicrobial drug development is increasingly lagging behind the evolution of antibiotic resistance as a result there is a pressing need for new antibacterial therapies that can be readily designed. Khansa. . Bukhari. Maryum. . Zeb. . History and Definition. Frederick . Twort. (1915) and Felix . d'Herelle. (1917) were the first to recognize bacteriophage.. In the 1930s and after words virologists utilized these viruses as model systems to investigate many aspects of virology. Yang Xin. Paper presentation. PNAS 2009, 106(12):4629-4634. Introduction. Antimicrobial drug development is increasingly lagging behind the evolution of antibiotic resistance. as a result, there is a pressing need for new antibacterial therapies that can be readily designed. William Brooks. Medicinal Chemistry. March 31, 2011. Outline. Conventional drug design vs. gene therapy. Examples of genetic engineering. Types of gene therapy. Mechanisms. Delivery vectors. Viral. Non-viral. By Kole Drumheller and Austin Dillard. Gene Therapy. What is Gene therapy?. This is a technique that is designed to introduce new genetic material into cells to help fix abnormal genes or to make a new protein that will help the person.. Pre-authorization vs. Post-prescription . Edina Avdic, . Pharm.D., . MBA, BCPS, AQ-ID. Associate . Director, Antimicrobial Stewardship . Program. Program Director, Infectious Diseases Pharmacy Residency . Maureen Campion, PharmD. Clinical Pharmacy Specialist- Infectious Disease. UMass Memorial Medical Center . Disclosure statement. I have no actual or potential conflict of interest . in relation to this program/presentation.. Naoki Yoshimura. Department of Urology. University of Pittsburgh School of Medicine. Annual CAIRIBU Meeting 2021. SESSION 4: Therapeutic Advances in Benign Genitourinary Research. NIH/NIDDK U54 DK112079. Genetic Counseling. Treating . Genetic . Disease. Removing . an affected body . part.. Replacing . an affected body part or biochemical . with material . from a . donor.. Delivering . pure, human proteins derived . 6000. inherited human diseases catalogued to date, only a few are currently treatable.. Gene therapy. —introducing functional copies of a gene into an individual with two defective copies of the gene—is a potential tool for treating inherited human diseases.. Gene therapy . is when DNA is introduced into a patient to treat a genetic disease. The new DNA usually contains a functioning gene to correct the effects of a disease-causing mutation. . Gene therapy uses sections of DNA (usually genes) to treat or prevent disease. The DNA is carefully selected to correct the effect of a mutated gene that is causing disease. The technique was first developed in 1972 but has, so far, had limited success in treating human diseases. Gene therapy may be a promising treatment option for some genetic diseases, including . Cell therapy is defined as the administration of live whole cells or maturation of a specific cell population in a patient for the treatment of a disease. . – Bone Marrow Transplantation. Bone . Marrow Transplantation for DBA. Peter Marks, MD, PhD. National Press Foundation. November 17, 2023. Outline. Status of gene therapy and genome editing. Regulatory considerations for genome editing. Regulatory guidance for genome editing. (…and NINDS’ Adaptations). John D. Porter, Ph.D.. Program Director. National Institute of Neurological Disorders and Stroke. National Institutes of Health. MSG Conference: 9/22/2014. 2. Gene Therapy's Second Act. Starter: Comparing DNA processes. Process. What does it do?. How does it work?. PCR (Polymerase Chain. Reaction). DNA Sequencing. DNA Profiling. Gel Electrophoresis. Process. What does it do?. How does it work?.
Download Document
Here is the link to download the presentation.
"Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents